Gå til innholdet
Global sound
SHTG Daily Digest — Weiss Lab

SHTG Daily Digest — Weiss Lab

av Ethan Weiss

Nyeste episode
SHTG Digest — Tuesday October 6, 2026

Om denne podkasten

Daily research digest on severe hypertriglyceridemia, ANGPTL3, ANGPTL4, APOC3, and lipoprotein lipase. Auto-generated from PubMed for Ethan Weiss.

Episoder

De 20 nyeste av 54 episoder

  • SHTG Digest — Tuesday October 6, 2026 · 5 minA thin cycle on both fronts — no new top-tier lipid papers after dedup, so this episode leans on two next-tier LPL papers (one showing FCS patients from Ionis' Balance trial…
  • SHTG Digest — Friday October 2, 2026 · 7 minA thin cycle on both fronts — the only top-tier lipid paper is the NEJM letter showing one-year durability of CTX310, CRISPR Therapeutics' one-time ANGPTL3 knockout, and the…
  • SHTG Digest — Tuesday September 29, 2026 · 7 minA thin cycle on both sides: no top-tier lipid papers, but the next tier brought a network meta-analysis finding that faster triglyceride lowering in HTG pancreatitis has not been…
  • SHTG Digest — Monday September 28, 2026 · 7 minAnother thin cycle: no top-tier lipid papers, but the next tier brought a high-specificity Cas12a editing study that knocked out Angptl3 in mice and a 526-patient study showing…
  • SHTG Digest — Friday September 25, 2026 · 13 minA thin cycle on both fronts — the lipid literature offered only next-tier work (an ANGPTL3 base-editing delivery study, an APOC3 variant association in Indian MASLD, and two…
  • SHTG Digest — Tuesday September 22, 2026 · 7 minIt's a thin cycle on both fronts — the only notable lipid-biology paper this week is a new CRISPR rabbit model of APOA5-driven hypertriglyceridemia, and the SHTG-relevant…
  • SHTG Digest — Saturday September 19, 2026 · 6 minA quiet cycle on both fronts — the lipid literature offered only next-tier evidence (CRISPR/base-editing for ANGPTL3, plasma exchange for SHTG crises, and an erythritol-apoC-III…
  • SHTG Digest — Friday September 18, 2026 · 7 minA new JACC: Basic to Translational Science analysis shows ApoC-III inhibition with olezarsen strips triglycerides and cholesterol out of Lp(a) particles without lowering Lp(a)…
  • SHTG Digest — Tuesday September 15, 2026 · 7 minA quiet cycle on both fronts — PubMed's top-tier journals produced zero SHTG/ANGPTL/APOC3/LPL hits this week (next-best-tier picks below cover ANGPTL3 inhibition, lipodystrophy…
  • SHTG Digest — Friday September 11, 2026 · 7 minNo top-tier journal papers cleared the bar this cycle, but next-tier literature offered genetics-to-therapy signal on FCS (a novel APOA5 variant and an ApoC-II case series)…
  • SHTG Digest — Tuesday September 8, 2026 · 7 minIt's a quiet cycle on both fronts — no top-tier-journal lipid papers cleared the bar, but the biggest industry story is a jolt: Novartis and Ionis's Lp(a)-lowering drug…
  • SHTG Digest — Friday September 4, 2026 · 7 minA quiet cycle on both fronts — no top-tier lipid papers cleared the bar in PubMed this week, and no genuinely new SHTG/Arrowhead/Alnylam/Ionis industry stories broke in the last…
  • SHTG Digest — Tuesday September 1, 2026 · 8 minThis is a quiet, largely repeat cycle — the CTX310 (ANGPTL3 base-editing) durability letter and the Arrowhead-vs-Ionis ESC Congress safety showdown that drove the last digest…
  • SHTG Digest — Monday August 31, 2026 · 7 minESC Congress in Munich delivered the payoff this cycle predicted last time — CRISPR Therapeutics published one-year durability data for its ANGPTL3 base-editing candidate CTX310…
  • SHTG Digest — Friday August 28, 2026 · 7 minNo new top-tier lipid papers broke this cycle, but a strong human ANGPTL3-deficiency kinetics study and a novel TREM2–APOC3 mechanism paper stood out on the science side, while…
  • SHTG Digest — Tuesday August 25, 2026 · 7 minNo top-tier-journal SHTG papers landed this cycle, but a broadened PubMed pull surfaced two drug-focused reviews on plozasiran and olezarsen plus a Korean GWAS turning up a novel…
  • SHTG Digest — Friday August 21, 2026 · 7 minNo top-tier journal papers on SHTG/ANGPTL/APOC3/LPL cleared the bar this cycle (next-best-tier picks below on ANGPTL3 inhibition and APOC3-targeted siRNA are still worth a read)…
  • SHTG Digest — Tuesday August 18, 2026 · 7 minNo top-tier trial readouts this cycle, but the science side keeps chipping at the APOC3/ANGPTL3/ANGPTL4/LPL mechanism (postprandial handling, CKD dyslipidemia, pancreatitis risk…
  • SHTG Digest — Friday August 14, 2026 · 7 minA quiet cycle on both fronts — the only qualifying PubMed hit is a JAMA news synopsis recapping June's Tryngolza approval rather than new primary research, and no fresh…
  • SHTG Digest — Tuesday August 11, 2026 · 7 minNo new top-tier journal papers this cycle — the science side is quiet reviews and case reports on the APOC3/LPL axis — while on the industry side Arrowhead bought itself a…

Live, siste time: 7 174 låter på 2 802 stasjoner i 114 land

Oppdag verden gjennom radioen

Flere måter å oppdage på (9)

Hørt noe fint? Lagre det, eller åpne det rett i Spotify.

★ Artist of the week The fastest riser on the radio this week
Your song here? From € 9 per week →
EGX UndergroundFortsett å lytte